Steven Cohen’s Esperion Therapeutics ESPR Stock Holding History

Steven Cohen’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-260,000	Closed	-$577K	–	2088
2024 Q2	$577K	Buy	260,000 +60,000	+30%	+$141K	﹤0.01%	1405
2024 Q1	$536K	Buy	+200,000	New	+$486K	﹤0.01%	1629
2023 Q1	–	Sell	-150,000	Closed	-$935K	–	2319
2022 Q4	$935K	Buy	150,000 +100,000	+200%	+$715K	﹤0.01%	1061
2022 Q3	$335K	Buy	+50,000	New	+$343K	﹤0.01%	1218

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Steven Cohen's ESPR Position: Q2 2026 in Review

Steven Cohen sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 1,689,372 shares — an estimated $4.63M sold.

Steven Cohen first reported a position in ESPR in Q4 2014 and held it in 21 quarters. The position peaked at $22.5M in Q3 2018. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Steven Cohen reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,689,372 Esperion Therapeutics shares in Q2 2026, an estimated $4.63M.
Steven Cohen first reported a position in Esperion Therapeutics in Q4 2014 and held it in 21 quarters.
Steven Cohen's Esperion Therapeutics position peaked at $22.5M in Q3 2018.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.